Modalim (Ciprofibrate)

Ciprofibrate activates the nuclear receptor PPARα, which increases the oxidation of fatty acids in the liver and reduces the synthesis of triglycerides. This biochemical shift leads to lower circulating triglyceride concentrations and a modest rise in HDL‑cholesterol.

The prescribed dose of Modalim is determined by the treating physician based on the patient’s lipid profile, renal and hepatic function, and concomitant medications. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for ciprofibrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Modalim product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with statins, ciprofibrate primarily lowers triglycerides rather than LDL‑cholesterol. It is often used when triglyceride levels are the main concern or when statins alone are insufficient. Unlike omega‑3 fatty acids, ciprofibrate works through PPARα activation, offering a distinct mechanism of action.

Modalim should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Modalim is taken orally, usually once daily with a meal to enhance absorption. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious adverse events include rhabdomyolysis, severe liver injury, and life‑threatening allergic reactions such as anaphylaxis. Patients should be educated to report unexplained muscle pain, weakness, dark urine, jaundice, or signs of hypersensitivity promptly.

Modalim is contraindicated in patients with known hypersensitivity to ciprofibrate or other fibrates, active liver disease, severe renal impairment, and in those taking gemfibrozil. Caution is also advised for individuals on high‑dose statins or anticoagulants, and the drug should be avoided during pregnancy unless clearly indicated.